CONNECT WITH US
HealthTech

HealthTech

Remission achievable with usual care for axial spondyloarthritis

Medical Xpress logo

Published on

Add as a preferred source on Google
Remission achievable with usual care for axial spondyloarthritis

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

For patients with axial spondyloarthritis (axSpA), remission is attainable with usual care, according to a study published in the Journal of Rheumatology.

Franziska Kluempers, M.D., from Universität Bochum in Germany, and colleagues examined remission rates in axSpA using cross-sectional data in a study of 200 adult patients with two or more prior visits, who were studied for a mean of 82.6 months.

The researchers found that at the enrollment visit, the mean Axial Spondyloarthritis Disease Activity Score (ASDAS) was 2.0. During observation, 58.5% of patients achieved ASDAS remission at least once. Remission was reached at 37.7 months after the start of hospital treatment.

Overall, 37.6%, 17.1%, 11.1% and 34.2% of patients achieved remission within the first year, after the first year, after two years and after three years, respectively. The mean duration of remission was 9.9 months.

Sustained remission for six or more consecutive months was achieved by 43.6% of patients. Associations were seen for higher C-reactive protein and lower Bath Ankylosing Spondylitis Disease Activity Index at the index visit with achieving remission at least once (odds ratios, 1.35 and 0.72, respectively).

"These data demonstrate that, for a sizable proportion of patients, remission is possible," the authors write.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.